iRadimed Corporation

IRMD Healthcare Medical Devices

iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024.

Revenue
+14.2%
EPS
+15.9%
Free cash flow
+18.6%

Quarter to September 2026, against a year earlier

86.17 0.63 +0.74%
Market cap
$1.1B
P/E
44.9×
Fwd P/E
39.6×
Dividend yield
0.91%
F-score
6/9
Altman Z
55.62
Beneish M
−2.55
Dividend safety
40/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
89.34 86.34 86.28 83.81

+8 more TTM periods

Gross Profit
67.46 65.50 66.30 64.32
Operating Income
28.86 27.56 27.95 26.15
EBT
31.12 29.75 30.19 28.36
Income after Tax
23.99 23.06 23.61 22.48
Net Income Common
23.99 23.06 23.61 22.48
EPS (Diluted)
1.87 1.79 1.83 1.75
Shares (Diluted, Weighted)
12.87 12.86 12.85 12.84
Gross Margin
75.51% 75.86% 76.84% 76.75%
EBIT Margin
32.30% 31.91% 32.40% 31.20%
Net Profit Margin
26.85% 26.70% 27.36% 26.82%
Free Cash Flow Margin
28.66% 28.43% 27.78% 19.72%
EBITDA
30.52 29.18 29.38 27.31
EBIT
28.86 27.56 27.95 26.15

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026